Kolon Life Science Inc.

A102940

KR7102940004

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 28/05/2024 am IST			5-day change	1st Jan Change
22,500 ^KRW	+1.58%		+1.81%	-12.45%

20/03	Kolon Life Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
05/03	Kolon Biotech, Inc. announced that it has received KRW 2.001 billion in funding from Kolon Life Science Inc.	CI

Kolon Life Science Inc. announced that it has received KRW 40 billion in funding

December 10, 2021

On December 10, 2021, Kolon Life Science Inc. closed the transaction. The company has raised KRW 25,000,000,000 in its Series 3 unregistered coupon nonguaranteed private convertible bond in final tranche bringing total proceeds to KRW 40,000,000,000.

Latest news about Kolon Life Science Inc.

Kolon Life Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
Kolon Biotech, Inc. announced that it has received KRW 2.001 billion in funding from Kolon Life Science Inc.	05/03	CI
Kolon Biotech, Inc. announced that it expects to receive KRW 2.0068 billion in funding from Kolon Life Science Inc.	17/01	CI
Kolon Life Science Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Kolon Life Science Inc.(KOSDAQ:A102940) added to S&P Global BMI Index	18/23/18	CI
Kolon Life Science Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Kolon Biotech, Inc. announced that it has received KRW 5.112 billion in funding from Kolon Life Science Inc.	21/23/21	CI
Kolon Biotech, Inc. announced that it expects to receive KRW 5.112 billion in funding from Kolon Life Science Inc.	12/23/12	CI
Kolon Life Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Kolon Biotech, Inc. announced that it expects to receive KRW 994 million in funding from Kolon Life Science Inc.	09/23/09	CI
Kolon Biotech, Inc. announced that it expects to receive KRW 1.5 billion in funding from Kolon Life Science Inc.	11/23/11	CI
Kolon Biotech, Inc. announced that it expects to receive KRW 1.005 billion in funding from Kolon Life Science Inc.	28/23/28	CI
Kolon Life Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
Kolon Biotech, Inc. announced that it expects to receive KRW 2.511 billion in funding from Kolon Life Science Inc.	19/23/19	CI
Kolon Life Science Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Kolon Biotech, Inc. announced that it expects to receive KRW 2.499 billion in funding from Kolon Life Science Inc.	18/22/18	CI
Kolon Life Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/22/16	CI
Kolon Biotech, Inc. announced that it has received KRW 5.562 billion in funding from Kolon Life Science Inc.	26/22/26	CI
Kolon Biotech, Inc. announced that it expects to receive KRW 5.562 billion in funding from Kolon Life Science Inc.	25/22/25	CI
Kolon Biotech, Inc. announced that it has received KRW 5.06 billion in funding from Kolon Life Science Inc.	19/22/19	CI
Kolon Life Science Enters $600 Million Deal to License out Gene Therapy Drug to Singapore's Juniper Biologics	14/22/14	MT
Juniper Biologics Pte Ltd Acquires Cell-Mediated Gene Therapy TG-C LD for Treatment of Knee Osteoarthritis	13/22/13	CI
Kolon Life Science Inc.(KOSDAQ:A102940) dropped from S&P Global BMI Index	21/22/21	CI
Kolon Life Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	16/22/16	CI
Kolon Life Science Inc. announced that it has received KRW 40 billion in funding	10/21/10	CI

Chart Kolon Life Science Inc.

Duration

Period

More charts

Company Profile

KOLON LIFE SCIENCE Inc. is a Korea-based company mainly engaged in the manufacturing of functional materials. The Company operates its business under two segments. The Chemical Business segment produces and sells raw drug products, which are the raw materials of new drugs and generic drugs, antibacterial agents that suppress bacterial growth, water treatment agents for environmental purification, and functional material products for cosmetics. The Bio Business segment manufactures and sells bio new medicines based on cell gene therapy products.

Sector

Pharmaceuticals

Calendar

14/05/2025 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KOLON LIFE SCIENCE INC.	-12.45%	19Cr
ELI LILLY AND COMPANY	+38.59%	73TCr
JOHNSON & JOHNSON	-7.89%	35TCr
MERCK & CO., INC.	+15.66%	33TCr
ABBVIE INC.	+0.24%	28TCr
ASTRAZENECA PLC	+13.47%	24TCr
NOVARTIS AG	+7.35%	21TCr
ROCHE HOLDING AG	-6.42%	20TCr
AMGEN INC.	+4.23%	16TCr
PFIZER, INC.	-1.70%	16TCr